Managed Healthcare is a leading brand offering a range of innovative products and services in the field of healthcare. With a focus on cost-effectiveness and evidence-based treatments, Managed Healthcare aims to provide effective solutions to meet the needs of patients and healthcare providers. One of their cutting-edge treatments is Hemgenix, a gene therapy for hemophilia B.

While Hemgenix has been approved conditionally by the Medicines and Healthcare products Regulatory Agency (MHRA), the National Institute for Health and Care Excellence (NICE) has raised concerns about its effectiveness and long-term durability based on the evidence from the pivotal clinical trial. Managed Healthcare is committed to improving patient access and outcomes. They offer a comprehensive range of resources, including informative publications, expert interviews, podcasts, and conferences, to keep healthcare professionals up-to-date with the latest developments in the field.

Although NICE has recommended against the use of Hemgenix for now, Managed Healthcare remains confident in the potential of this groundbreaking therapy and continues to advocate for its use in eligible patients. They believe Hemgenix could bring about long-lasting therapeutic benefits and contribute to better outcomes for individuals with hemophilia B